HasenTech Inc. is an early-stage biotech start-up developing a novel anti-inflammatory exopolysaccharide (EPS) from Bacillus subtilis to treat inflammatory diseases, with an initial focus on graft versus host disease (GvHD). HasenTech is collaborating with clinical expert and regulatory consultants to design first-in-human (FIH) trials. Specific objectives of the NSF ART project include developing an activity assay for EPS, scaling up manufacturing, optimizing purification, and preparing for FIH studies with the FDA.
Join the National NSF ART Network – Submit the Membership Request Form
